Anaplastic Large-cell Lymphoma

Showing 1 - 5 of 5

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma Trial in Worldwide (brentuximab vedotin, doxorubicin,

Completed
  • Anaplastic Large-Cell Lymphoma
  • +2 more
  • brentuximab vedotin
  • +4 more
  • Gilbert, Arizona
  • +143 more
Nov 1, 2021

Hodgkin Lymphoma, Anaplastic Large-cell Lymphoma Trial in Belgium, Lithuania, Spain (brentuximab vedotin, Brentuximab vedotin

Completed
  • Hodgkin Lymphoma
  • Anaplastic Large-cell Lymphoma
  • brentuximab vedotin
  • Brentuximab vedotin and rifampicin
  • Brussels, Belgium
  • +5 more
Mar 30, 2016

Anaplastic Large-Cell Lymphoma Trial in United States (SGN-30 (anti-CD30 mAb))

Completed
  • Anaplastic Large-Cell Lymphoma
  • SGN-30 (anti-CD30 mAb)
  • Birmingham, Alabama
  • +17 more
Dec 17, 2014

Anaplastic Large-Cell Lymphoma Trial in New York (Denileukin Diftitox, Denileukin diftitox, ifosfamide, cyclophosphamide,

Withdrawn
  • Anaplastic Large-Cell Lymphoma
  • Denileukin Diftitox
  • Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
  • New York, New York
    Columbia University Medical Center
May 14, 2013